Eisai Co., Ltd. announced that the in-house discovered and developed orexin receptor antagonist Dayvigo (brand name in China: “达卫可®“ generic name: lemborexant) has launched in China for the… read more.
Over an 18-month period, patients suffering with insomnia who were treated with cannabis- based medical products reported improvement in sleep. The findings were published on Aug. 27, 2025… read more.
Vanda Pharmaceuticals Inc. announced that on February 4, 2024, it received a notification from the FDA stating that as part of its ongoing review of Vanda’s supplemental New… read more.
Although most patients diagnosed with Covid-19 will quickly recover, some people experience symptoms that linger well after they start testing negative again — including insomnia. Scientists already knew… read more.
A new study shows that using a weighted blanket at bedtime increases melatonin in young adults. This hormone increases in response to darkness, and some evidence suggests that… read more.
In recent years, the number of people worldwide who are dissatisfied or anxious about their sleep has been increasing due to the diversification of lifestyles. Simple sleep measurement… read more.
A new study revealed that a talk therapy practice conducted by telephone could help older adults who have arthritis-related insomnia sleep better. The study was published in the Journal of the… read more.
Insomnia may be a potential risk factor for a brain bleed from a ruptured aneurysm along with more well known risk factors of smoking and high blood pressure,… read more.
Article written by Gary Finnegan More than a third of medical staff suffered insomnia during the COVID-19 epidemic in China, according to a new study.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
